Abstract
AbstractThe generation of an anti-malarial vaccine that produces broad, potent, and durable responses is highly desirable to control the burden ofPlasmodium falciparumdisease. Current vaccines have offered modest efficacy ranging from 50%-70%, likely associated with antibody responses that are relatively short lived and strain specific. Currently approved malaria vaccines, RTS,S and R21, target the repeat region and C-terminal region ofPlasmodium falciparumCSP, leaving the N-terminal region of CSP neglected as a target for protective immunogen design. Here, we isolate and express a panel of memory B-cell derived N-terminal CSP-specific monoclonal antibodies (mAbs) from mice immunized with an N-terminal CSP specific immunogen. The characterization of N-terminal specific mAbs including peptide walking and affinity experiments indicate that these antibodies target three distinct sites within the N-terminus of CSP. Site ntCSP-A contains the Region I (RI) cleavage site, which has been previously defined, whereas the remaining two sites are in previously undescribed locations upstream of RI, termed ntCSP-B and ntCSP-C.
Publisher
Cold Spring Harbor Laboratory
Reference35 articles.
1. WHO. World Malaria Report 2023. (2023).
2. Artemisinin resistance – modelling the potential human and economic costs
3. World Health Organization. Artemisinin resistance and artemisinin-based combination therapy efficacy: status report. (World Health Organization, 2018).
4. World Health Organization. Global Technical Strategy for Malaria 2016–2030. (World Health Organization, 2015).
5. First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children